A5009634950- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Renal cell carcinoma treatment
- Toxin Mechanisms and Immunotoxins
- CRISPR and Genetic Engineering
- Genetic factors in colorectal cancer
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- Cervical Cancer and HPV Research
- Cancer Risks and Factors
- DNA Repair Mechanisms
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Estrogen and related hormone effects
- Cancer Mechanisms and Therapy
Agostino Gemelli University Polyclinic
2021-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2024
Vall d'Hebron Hospital Universitari
2024
Vall d'Hebron Institute of Oncology
2024
Policlinico Umberto I
2019-2021
Sapienza University of Rome
2019-2021
Importance Various randomized trials have explored the efficacy of combining immune checkpoint inhibitors (ICIs) with first-line chemotherapy in advanced endometrial cancer. We aimed to summarize available data and clarify benefit adding immunotherapy according DNA mismatch repair status (deficient, dMMR or proficient, pMMR) specific type agent used (anti-PD1 anti-PD-L1). Objective To assess whether addition ICIs standard platinum-based enhances progression-free survival (PFS) for patients...
Adnexal masses are not common in pregnancy. They often discovered incidentally during routine ultrasound examinations. In general, 24%–40% of the cases benign tumors; up to 8% malignant tumors. usually asymptomatic, but sometimes can be responsible for abdominal or pelvic pain. Transvaginal and transabdominal is essential define morphology distinguish between cases. Magnetic resonance imaging a complementary examination when findings equivocal useful additional better tissue planes relations...
Platinum-resistant ovarian cancer patients have a poor prognosis and few treatment options are available. Preclinical clinical data demonstrated that the combination of poly-ADP ribose polymerase inhibitors with immune checkpoint could synergistic antitumor activity in this setting patients.The primary objective is to assess efficacy niraparib plus dostarlimab compared chemotherapy recurrent not suitable for platinum treatment.This trial will hypothesis therapy effective increase overall...
Immune checkpoint blockers (ICB) act by reverting the immunosuppressive phenotype of cancer cells, thus allowing host immune system to generate an response tumor. One key mechanisms targeted ICB is PD-1/PD-L1 axis, which lies onto interaction between programmed-cell death protein 1 and its ligand, overexpressed in several tumor types. This leads inhibition T-cell proliferation their apoptosis exhaustion. Anti-PD-1/PD-L1 monoclonal antibodies are now mainstay treatment for advanced stage...
The emerging era of precision medicine is characterized by an increasing availability targeted anticancer therapies and the parallel development techniques to obtain more refined molecular data, whose interpretation may not always be straightforward. Molecular tumor boards gather various professional figures, in order leverage analysis data provide prognostic predictive insights for clinicians. In addition healthcare development, they could also become a tool promote knowledge research...